STOCK TITAN

[8-K] Citius Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Citius Pharmaceuticals reported that it posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 in an Item 7.01 Regulation FD disclosure. The company noted that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in a future filing.

Citius Pharmaceuticals ha comunicato di aver pubblicato una presentazione aziendale aggiornata sul proprio sito web e di averla fornita come Exhibit 99.1 in una disclosure ai sensi della Regola FD (Item 7.01). L'azienda ha osservato che queste informazioni non sono considerate "depositate" ai sensi della Sezione 18 della Exchange Act e non sono incorporate per riferimento a meno che non siano specificamente richiamate in una futura comunicazione/ deposito.

Citius Pharmaceuticals informó que publicó una Presentación Corporativa actualizada en su sitio web y la presentó como Exhibit 99.1 en una divulgación conforme a la Regla FD, de un Ítem 7.01. La empresa señaló que esta información no se considera "presentada" conforme a la Sección 18 de la Exchange Act y no se incorpora por referencia a menos que se haga referencia específica en un depósito futuro.

Citius Pharmaceuticals는 자사 웹사이트에 업데이트된 기업 프레젠테이션을 게시했고 이를 Item 7.01 Regulation FD 공시에 Exhibit 99.1로 제출했다고 밝혔다. 회사는 이 정보가 Exchange Act의 제18조에 따라 "공시된" 것으로 간주되지 않으며 향후 제출 서류에 구체적으로 참조되지 않는 한 참조로 통합되지 않는다고 지적했다.

Citius Pharmaceuticals a indiqué avoir publié une présentation d'entreprise mise à jour sur son site web et l'a fournie comme Exhibit 99.1 dans le cadre d'une divulgation selon l'article 7.01 de Regulation FD. La société a noté que ces informations ne sont pas considérées comme “dépôtées” au titre de l'article 18 de la Exchange Act et ne sont pas incorporées par référence sauf si elles sont spécifiquement mentionnées dans un dépôt futur.

Citius Pharmaceuticals gab bekannt, dass es eine aktualisierte Unternehmenspräsentation auf seiner Website veröffentlicht hat und sie als Exhibit 99.1 in einer Offenlegung nach Item 7.01 Regulation FD vorgelegt hat. Das Unternehmen wies darauf hin, dass diese Informationen gemäß Abschnitt 18 des Exchange Act nicht als "eingereicht" gilt und nicht durch Bezugnahme einbezogen wird, es sei denn, sie wird in einer zukünftigen Einreichung ausdrücklich referenziert.

Citius Pharmaceuticals أفادت بأنها نشرت عرضاً تقديمياً محدثاً للشركة على موقعها الإلكتروني وأرفقته ك Exhibit 99.1 في إفصاح وفق Regulation FD وبند 7.01. أشارت الشركة إلى أن هذه المعلومات لا تعتبر "مُدرَجة" بموجب القسم 18 من قانون التداول (Exchange Act) ولا يتم إدراجها بالاعتماد عليها ما لم يُشار إليها صراحة في تقديم مستقبلي.

Citius Pharmaceuticals 公司表示已在其网站上发布了更新的公司介绍,并将其作为 Exhibit 99.1 提交于基于 Regulation FD 的披露中的 Item 7.01。公司指出,该信息不被视为根据《证券交易法》第18条的“备案”信息,也不通过引用被纳入,除非在未来的备案中被明确引用。

Positive
  • None.
Negative
  • None.

Citius Pharmaceuticals ha comunicato di aver pubblicato una presentazione aziendale aggiornata sul proprio sito web e di averla fornita come Exhibit 99.1 in una disclosure ai sensi della Regola FD (Item 7.01). L'azienda ha osservato che queste informazioni non sono considerate "depositate" ai sensi della Sezione 18 della Exchange Act e non sono incorporate per riferimento a meno che non siano specificamente richiamate in una futura comunicazione/ deposito.

Citius Pharmaceuticals informó que publicó una Presentación Corporativa actualizada en su sitio web y la presentó como Exhibit 99.1 en una divulgación conforme a la Regla FD, de un Ítem 7.01. La empresa señaló que esta información no se considera "presentada" conforme a la Sección 18 de la Exchange Act y no se incorpora por referencia a menos que se haga referencia específica en un depósito futuro.

Citius Pharmaceuticals는 자사 웹사이트에 업데이트된 기업 프레젠테이션을 게시했고 이를 Item 7.01 Regulation FD 공시에 Exhibit 99.1로 제출했다고 밝혔다. 회사는 이 정보가 Exchange Act의 제18조에 따라 "공시된" 것으로 간주되지 않으며 향후 제출 서류에 구체적으로 참조되지 않는 한 참조로 통합되지 않는다고 지적했다.

Citius Pharmaceuticals a indiqué avoir publié une présentation d'entreprise mise à jour sur son site web et l'a fournie comme Exhibit 99.1 dans le cadre d'une divulgation selon l'article 7.01 de Regulation FD. La société a noté que ces informations ne sont pas considérées comme “dépôtées” au titre de l'article 18 de la Exchange Act et ne sont pas incorporées par référence sauf si elles sont spécifiquement mentionnées dans un dépôt futur.

Citius Pharmaceuticals gab bekannt, dass es eine aktualisierte Unternehmenspräsentation auf seiner Website veröffentlicht hat und sie als Exhibit 99.1 in einer Offenlegung nach Item 7.01 Regulation FD vorgelegt hat. Das Unternehmen wies darauf hin, dass diese Informationen gemäß Abschnitt 18 des Exchange Act nicht als "eingereicht" gilt und nicht durch Bezugnahme einbezogen wird, es sei denn, sie wird in einer zukünftigen Einreichung ausdrücklich referenziert.

false 0001506251 0001506251 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) October 23, 2025

  

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

  

Nevada

(State or other jurisdiction of incorporation)

 

001-38174   27-3425913
(Commission File Number)   (IRS Employer Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ   07016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (908) 967-6677

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   CTXR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On October 23, 2025, Citius Pharmaceuticals, Inc. posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibit is filed herewith:

 

Exhibit No.   Description
     
99.1   Corporate Presentation of October 2025.
     
104   Cover Page Interactive Date File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CITIUS PHARMACEUTICALS, INC.
   
Date: October 23, 2025 /s/ Leonard Mazur
  Leonard Mazur
  Chairman and Chief Executive Officer

 

2

 

FAQ

What did Citius Pharmaceuticals (CTXR) announce in this 8-K?

The company posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 under Item 7.01 (Regulation FD).

Is the Corporate Presentation deemed 'filed' for liability purposes?

No. The company states the Item 7.01 information (including Exhibit 99.1) is not deemed “filed” under Section 18 of the Exchange Act.

Where can I find the presentation referenced by CTXR?

It is attached as Exhibit 99.1 to the report and is posted on the company’s website.

What is the date of the reported event for CTXR?

October 23, 2025.

Which executive signed the report for CTXR?

Leonard Mazur, Chairman and Chief Executive Officer.

What other exhibit is included in the filing?

Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.
Citius Pharmaceuticals Inc

NASDAQ:CTXR

CTXR Rankings

CTXR Latest News

CTXR Latest SEC Filings

CTXR Stock Data

28.58M
16.52M
2.9%
5.46%
4.68%
Biotechnology
Pharmaceutical Preparations
Link
United States
CRANFORD